Restoration of normal phenotype in cancer cells

Title: Restoration of normal phenotype in cancer cells

Full Record
Other Related Research

Abstract

A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying .beta..sub.1 integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive.

Inventors:

Bissell, Mina J. ^[1]; Weaver, Valerie M. ^[2]

(Berkeley, CA)
(Oakland, CA)

Issue Date:: 1998-01-01

Research Org.:: Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA

OSTI Identifier:: 872022

Patent Number(s):: 5846536

Assignee:: Regents of University of California (Oakland, CA) LBNL

DOE Contract Number:: AC03-76SF00098

Resource Type:: Patent

Country of Publication:: United States

Language:: English

Subject:: restoration; normal; phenotype; cancer; cells; method; reversing; expression; malignant; described; comprises; applying; beta; integrin; function-blocking; antibody; assess; progress; therapy; human; breast; epithelial; shown; particularly; responsive; method comprises; cancer therapy; comprises applying; method comprise; epithelial cells; cancer cells; reversing expression; normal phenotype; function-blocking antibody; integrin function-blocking; malignant phenotype; /424/530/

Citation Formats


                    Bissell, Mina J., and Weaver, Valerie M. Restoration of normal phenotype in cancer cells.  United States: N. p., 1998. 
        Web.

Copy to clipboard


                    Bissell, Mina J., & Weaver, Valerie M. Restoration of normal phenotype in cancer cells.  United States.

Copy to clipboard


                    Bissell, Mina J., and Weaver, Valerie M. Thu .  
        "Restoration of normal phenotype in cancer cells".  United States.  https://www.osti.gov/servlets/purl/872022.

Copy to clipboard


                    
@article{osti_872022,

  title        = {Restoration of normal phenotype in cancer cells},

  author       = {Bissell, Mina J. and Weaver, Valerie M.},

  abstractNote = {A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying .beta..sub.1 integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {1998},

  month        = {1}

}

Copy to clipboard

Patent:

View Patent

Save / Share:

Export Metadata

Save to My Library

Similar records in DOE Patents and OSTI.GOV collections:

Method for restoration of normal phenotype in cancer cells

Patent Bissell, Mina J. (Berkeley, CA); Weaver, Valerie M. (Oakland, CA)

A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying .beta..sub.1 integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive.
Full Text Available
Restoration of normal phenotype in cancer cells

Patent Bissell, M.J.; Weaver, V.M.

A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying {beta}{sub 1} integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive. 14 figs.
Protocells and their use for targeted delivery of multicomponent cargos to cancer cells

Patent Brinker, C Jeffrey; Ashley, Carlee Erin; Jiang, Xingmao; ...

Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.
Full Text Available
Protocells and their use for targeted delivery of multicomponent cargos to cancer cells

Patent Brinker, Jeffrey C.; Ashley, Carlee Erin; Jiang, Xingmao; ...

Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.
Full Text Available
Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Patent Crissman, Harry A. (Los Alamos, NM); Gadbois, Donna M. (Los Alamos, NM); Tobey, Robert A. (Los Alamos, NM); ...

A G.sub.1 phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G.sub.1 phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G.sub.1 cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G.sub.1 phase, suggesting that such G.sub.1 phase kinase inhibitors may form an effective adjuvant for use with chemotherapeutic agents inmore »« less
Full Text Available

Similar Records